Table 2 Association between infiltrated metLN patterns and patients’ clinicopathological features

Gender

Male

161

142

19

4.169

0.041^*

Female

151

143

8

Age

≤60

158

142

16

0.878

0.349

>60

154

143

11

Smoke

Ever

92

78

14

7.110

0.008^*

Never

220

207

13

Tumor size

≤3 cm

160

150

10

2.401

0.121

>3 cm

152

135

17

Tumor location

RUL

86

80

6

7.055

0.133

RML

36

33

3

RLL

56

47

9

LUL

80

77

3

LLL

54

48

6

Driver mutation

EGFR

151

141

10

4.525

0.210

KRAS

34

29

5

FUSION

41

35

6

Wild-type

86

80

6

Vascular invasion

Absent

194

182

12

3.953

0.047^*

Present

118

103

15

pStage N

N1

164

155

9

4.384

0.036^*

N2

148

130

18

Primary tumor pathological classification (WHO)

Acinar

148

137

11

0.890

0.828

Papillary

70

64

6

Solid

61

55

6

Micropapillary

33

29

4

Metastatic LN pathological classification (WHO)

Acinar

118

112

6

6.751

0.080

Papillary

75

69

6

Solid

96

82

14

Micropapillary

23

22

1

LNR status

Low (<0.33)

206

196

10

11.073

0.001^*

High (>0.33)

106

89

17